BioSpace News Archive

Business

Boston Scientific Announces Results For Third Quarter 2021

Boston Scientific Corporation generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and 10.6 percent on an organic2 basis, all compared to the prior year period.

October 27, 2021
·
17 min read
Drug Development

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced the completion of enrollment in the company’s ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy.

October 27, 2021
·
6 min read
Business

Sharps Compliance Reports Fiscal 2022 First Quarter Results

Sharps Compliance Reports Fiscal 2022 First Quarter Results

October 27, 2021
·
15 min read
Biotech Bay

Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies

Nurix to host a conference call today at 8:30 a.m. ET

October 27, 2021
·
10 min read
Drug Development

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors

Bio-Path Holdings, Inc., today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug (IND) application to initiate a Phase 1/1b clinical trial of prexigebersen-A

October 27, 2021
·
5 min read
Drug Development

IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme

IN8bio today announced the peer-reviewed publication of preclinical results that provides foundational support for the use of DRI in newly diagnosed GBM.

October 27, 2021
·
5 min read
Drug Development

Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore

Adagene Inc. today announced the initiation of a phase 1b/2 clinical trial of the anti-CD137 agonist antibody, ADG106, in combination with the anti-PD-1 antibody, Nivolumab.

October 27, 2021
·
10 min read
BioMidwest

Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy

A new, patient-led research analysis published this week in the journal Neurology and Therapy reveals the lived experience of myasthenia gravis and calls for greater understanding of the reality of living with MG, through the eyes of the patient.

October 27, 2021
·
12 min read
FDA

PreludeDx™ Presents DCIS Precision Medicine Study Results at ASTRO 2021 Annual Meeting

Prelude Corporation presented data in an oral scientific session presentation at the American Society for Radiation Oncology (ASTRO) 63rd Annual Meeting held October 24 – 27, 2021 at McCormick Place West in Chicago, IL.

October 27, 2021
·
4 min read
Biotech Beach

NuVasive to Release Cutting-edge Virtual Reality Training for Lateral, Single-position Spine Surgery

NuVasive, Inc. (NASDAQ: NUVA), today announced the upcoming release of a cutting-edge virtual reality (VR) training module for the NuVasive X360® system to complement its market-leading Clinical Professional Development (CPD) program.

October 27, 2021
·
5 min read